Skip to main content
. 2022 Dec 28;11(1):96. doi: 10.3390/healthcare11010096

Table 1.

The 100 most-cited articles about midazolam considering the citation density.

Rankings
Density of Citation/No Citation, WoS-CC a 		Author/Year Density of Citation No Citation, WoS-CC a No. Citation, Scopus No. Citation, Google Scholar Study Object DOI/URL
01/24 Glauser et al., 2016 [13] 92.20 476 519 837 Epilepsy treatment https://doi.org/10.5698/1535-7597-16.1.48
02/10 Murrough et al., 2013 [15] 84.75 678 727 1031 Depression use https://doi.org/10.1176/appi.ajp.2013.13030392
03/01 Kress et al., 2000 [14] 83.05 1744 311 3494 Sedative effects https://doi.org/10.1056/NEJM200005183422002
04/04 Riker et al., 2009 [16] 80.83 970 1163 1720 Sedation aspects https://doi.org/10.1001/jama.2009.56
05/02 Jevtovic-Todorovic et al., 2003 [17] 75.94 1367 1553 2147 Anesthesia effects https://doi.org/10.1523/jneurosci.23-03-00876.2003
06/20 Ferguson et al., 2013 [18] 64.38 515 595 890 Sedation aspects https://doi.org/10.1056/NEJMoa1215554
07/22 Casali et al., 2013 [19] 60.88 487 532 787 Sedation aspects https://doi.org/10.1126/scitranslmed.3006294
08/03 Jacobi et al., 2002 [20] 59.95 1139 1483 2321 Sedation and analgesia aspects https://doi.org/10.1097/00003246-200201000-00020
09/19 Jakob et al., 2012 [21] 57.67 519 582 958 Sedation aspects https://doi.org/10.1001/jama.2012.304
10/17 Strøm et al., 2010 [22] 49.27 542 610 1006 Sedation aspects https://doi.org/10.1016/S0140-6736(09)62072-9
11/39 Silbergleit et al., 2012 [23] 43.00 387 460 674 Epilepsy treatment https://doi.org/10.1056/NEJMoa1107494
12/28 Needham et al., 2010 [24] 40.91 450 476 817 Sedation aspects https://doi.org/10.1016/j.apmr.2010.01.002
13/07 Lamba et al., 2002 [25] 38.84 738 806 1152 Cytochrome P450 approach https://doi.org/10.1016/S0169-409X(02)00066-2
14/06 Glass et al., 1997 [26] 36.86 884 1085 1850 Sedation aspects https://doi.org/10.1097/00000542-199704000-00014
15/31 Klotz, 2009 [27] 35.17 422 466 761 Historical aspects https://doi.org/10.1080/03602530902722679
16/37 Izzo & Ernst, 2009 [28] 32.75 393 460 982 Drug interactions https://doi.org/10.2165/11317010-000000000-00000
17/79 Mehta et al., 2012 [29] 32.44 292 330 519 Sedation aspects https://doi.org/10.1001/jama.2012.13872
18/64 Zhao et al., 2011 [30] 32.30 323 341 451 Pharmacology https://doi.org/10.1038/clpt.2010.298
19/11 Dresser et al., 2000 [31] 31.33 658 807 1115 Cytochrome P450 https://doi.org/10.2165/00003088-200038010-00003
20/05 Chernik et al., 1990 [32] 30.77 954 1071 1741 Sedation aspects https://doi.org/10.1097/00004714-199008000-00003
21/36 Greicius et al., 2008 [33] 30.54 397 421 600 Sedation aspects https://doi.org/10.1002/hbm.20537
22/08 Thummel & Wilkinson, 1998 [34] 30.26 696 128 1071 Cytochrome P450 approach https://doi.org/10.1146/annurev.pharmtox.38.1.389
23/95 Shorvon & Ferlisi, 2012 [35] 29.33 264 310 451 Epilepsy treatment https://doi.org/10.1093/brain/aws091
24/42 Verbeeck, 2008 [36] 28.46 370 466 599 Liver evaluation https://doi.org/10.1007/s00228-008-0553-z
25/43 Pan-dharipande et al., 2008 [37] 28.31 368 406 668 Risk factors https://doi.org/10.1097/TA.0b013e31814b2c4d
26/81 Ferrarelli et al., 2010 [38] 27.73 305 334 493 Anesthesia aspects https://doi.org/10.1073/pnas.0913008107
27/29 Hu et al., 2005 [39] 27.50 440 769 283 Pharmacology https://doi.org/10.2165/00003495-200565090-00005
28/26 Bowles et al., 2004 [40] 27.29 464 558 863 Sedation aspects https://doi.org/10.1136/gut.2003.016436
29/27 Li et al., 2004 [41] 27.29 464 508 775 Cytochrome P450 approach https://doi.org/10.1124/dmd.32.8.821
30/12 Paine et al., 1997 [42] 27.00 648 694 974 Cytochrome P450 approach https://jpet.aspetjour-nals.org/content/283/3/1552.long
31/25 Niemi et al., 2003 [43] 26.33 474 530 761 Pharmacology https://doi.org/10.2165/00003088-200342090-00003
32/82 Shehabi et al., 2010 [44] 26.27 289 327 445 Cytochrome P450 approach https://doi.org/10.1097/CCM.0b013e3181f85759
33/58 McQuaid & Laine, 2008 [45] 25.92 337 348 524 Sedation aspects https://doi.org/10.1016/j.gie.2007.12.046
34/49 Stevens et al., 2007 [46] 25.57 358 417 692 Risk factors https://doi.org/10.1007/s00134-007-0772-2
35/53 Payen et al., 2007 [47] 24.93 349 402 689 Analgesia and sedation aspects https://doi.org/10.1097/01.anes.0000264747.09017.da
36/90 Meierkord et al., 2010 [48] 24.64 271 327 488 Epilepsy treatment https://doi.org/10.1111/j.1468-1331.2009.02917.x
37/15 Kollef et al., 1998 [49] 24.00 552 713 1165 Sedation aspects https://doi.org/10.1378/chest.114.2.541
38/13 Cruz et al., 1994 [50] 23.93 646 676 929 Anxiety use https://doi.org/10.1016/0091-3057(94)90472-3
39/50 Johnson et al., 2006 [51] 23.73 356 380 509 Cytochrome P450 approach https://doi.org/10.2165/00003088-200645090-00005
40/18 Bailey et al., 1998 [52] 23.26 535 658 938 Food interaction https://doi.org/10.1046/j.1365-2125.1998.00764.x
41/74 Riss et al., 2008 [53] 23.00 299 345 541 Pharmacology https://doi.org/10.1111/j.1600-0404.2008.01004.x
42/38 Walsky & Obach, 2004 [54] 22.88 389 429 561 Cytochrome P450 approach https://doi.org/10.1124/dmd.32.6.647
43/48 Zhou et al., 2005 [55] 22.44 359 424 545 Cytochrome P450 approach https://doi.org/10.2165/00003088-200544030-00005
44/84 Lichtenstein et al., 2008 [56] 21.85 284 373 538 Guideline https://doi.org/10.1016/j.gie.2008.09.029
45/96 Maldonado et al., 2009 [57] 21.83 262 309 560 Sedation aspects https://doi.org/10.1176/appi.psy.50.3.206
46/57 Willoughby et al., 2005 [58] 21.50 344 432 675 Sedation aspects https://doi.org/10.1056/NEJMoa050382
47/23 Lowenstein & Alldredge, 1998 [59] 21.09 485 20 35 Epilepsy treatment https://doi.org/10.1056/NEJM199804023381407
48/68 Krauss & Green, 2006 [60] 21.07 316 365 607 Sedation and analgesia aspects https://doi.org/10.1016/S0140-6736(06)68230-5
49/60 Yon et al., 2005 [61] 20.63 330 378 508 Apoptotic pathways investigation https://doi.org/10.1016/j.neuroscience.2005.03.064
50/85 De Graeff & Dean, 2007 [62] 20.21 283 327 555 Clinical use https://doi.org/10.1089/jpm.2006.0139
51/41 Claassen et al., 2002 [63] 19.95 379 466 717 Epilepsy treatment https://doi.org/10.1046/j.1528-1157.2002.28501.x
52/32 Venkata-krishnan et al., 2000 [64] 19.90 418 474 642 Cytochrome P450 approach https://doi.org/10.2165/00003088-200038020-00002
53/67 Young et al., 2005 [65] 19.88 318 371 519 Neurodegeneration https://doi.org/10.1038/sj.bjp.0706301
54/21 Thummel et al., 1996 [66] 19.84 496 550 703 Cytochrome P450 approach https://doi.org/10.1016/S0009-9236(96)90177-0
55/09 Reves et al., 1985 [67] 19.00 684 750 1243 Midazolam pharmacology https://doi.org/10.1097/00000542-198503000-00017
56/16 Kauffman et al., 1992 [68] 19.72 543 501 645 Sedation aspects https://pennstate.pure.elsevier.com/en/publications/guidelines-for-monitoring-and-management-of-pediatric-patients-du-2
57/51 Lin et al., 2002 [69] 19.68 355 377 537 Cytochrome P450 approach https://doi.org/10.1124/mol.62.1.162
58/34 Kim et al., 1999 [70] 18.36 404 452 599 Cytochrome P450 approach https://doi.org/10.1023/a:1018877803319
59/44 Putensen et al., 2001 [71] 18.30 366 442 692 Acute respiratory https://doi.org/10.1164/ajrccm.164.1.2001078
60/14 Kronbach et al., 1989 [72] 17.47 559 529 688 Cytochrome P450 approach https://citeseerx.ist.psu.edu/view-doc/download?doi=10.1.1.989.1642&rep=rep1&type=pdf
61/30 Schuetz et al., 1996 [73] 17.36 434 495 641 Cytochrome P450 approach https://molpharm.aspetjournals.org/content/49/2/311.long
62/45 Streetman et al., 2000 [74] 17.29 363 404 536 Cytochrome P450 approach https://doi.org/10.1097/00008571-200004000-00001
63/88 McIntyre et al., 2005 [75] 17.06 273 330 505 Epilepsy treatment https://doi.org/10.1016/S0140-6736(05)66909-7
64/61 Dielenberg & McGregor, 2001 [76] 16.40 328 338 481 Behavioral and anxiety evaluation https://doi.org/10.1016/S0149-7634(01)00044-6
65/35 Paine et al., 1996 [77] 16.12 403 437 591 Cytochrome P450 approach https://doi.org/10.1016/S0009-9236(96)90162-9
66/66 Özdemir et al., 2000 [78] 15.19 319 350 487 Cytochrome P450 approach https://doi.org/10.1097/00008571-200007000-00001
67/54 Gorski et al., 1998 [79] 15.17 349 381 471 Cytochrome P450 approach https://doi.org/10.1016/S0009-9236(98)90146-1
68/83 Andrew Williams et al., 2002 [80] 14.95 284 322 551 Sedation aspects https://doi.org/10.1124/dmd.30.8.883
69/63 Venn et al., 1999 [81] 14.68 323 417 702 Comparison with other drugs https://doi.org/10.1046/j.1365-2044.1999.01114.x
70/80 Bai et al., 2001 [82] 14.55 291 303 445 GABA receptor https://doi.org/10.1124/mol.59.4.814
71/93 Yuan et al., 2002 [83] 14.11 268 303 429 Cytochrome P450 approach https://doi.org/10.1124/dmd.30.12.1311
72/77 Lang et al., 2000 [84] 14.10 296 390 660 Anesthesia and sedation aspects https://doi.org/10.1016/S0140-6736(00)02162-0
73/94 Gurley et al., 2002 [85] 13.89 264 293 397 Cytochrome P450 approach https://doi.org/10.1067/mcp.2002.126913
74/59 Schmiedlin-Ren et al., 1997 [86] 13.83 332 366 466 Cytochrome P450 approach https://molpharm.aspetjournals.org/content/51/5/741.long
75/87 Olkkola et al., 1994 [87] 13.33 360 498 786 Cytochrome P450 approach https://doi.org/10.1038/clpt.1994.60
76/71 Pelkonen et al., 1998 [88] 13.22 304 312 393 Cytochrome P450 approach https://doi.org/10.1080/004982598238886
77/13,18 Kenworthy et al., 1999 [89] 13.18 290 309 415 Cytochrome P450 approach https://doi.org/10.1046/j.1365-2125.1999.00073.x
78/81 Wang et al., 2001 [90] 13.10 262 328 452 Cytochrome P450 approach https://doi.org/10.1067/mcp.2001.118522
79/89 Krauss & Green, 2000 [91] 12.95 272 333 481 Sedation and analgesia aspects https://doi.org/10.1056/NEJM200003303421306
80/55 Christopher Gorski et al., 1994 [92] 12.81 346 368 479 Cytochrome P450 approach https://doi.org/10.1016/0006-2952(94)90543-6
81/40 Arrowsmith et al., 1991 [93] 12.77 383 450 595 Adverse effects https://doi.org/10.1016/S0016-5107(91)70773-6
82/52 Parke et al., 1992 [94] 12.14 352 475 697 Sedation aspects https://doi.org/10.1136/bmj.305.6854.613
83/100 Ostermann et al., 2000 [95] 12.05 253 323 552 Sedation aspects https://doi.org/10.1001/jama.283.11.1451
84/62 Lown et al., 1994 [96] 12.00 324 353 452 Cytochrome P450 approach https://dmd.aspetjour-nals.org/content/22/6/947.long
85/73 Kup-ferschmidt et al., 1995 [97] 11.65 303 345 439 Pharmacology https://doi.org/10.1016/0009-9236(95)90068-3
86/98 Scott et al., 1999 [3] 11.64 256 307 463 Epilepsy treatment https://doi.org/10.1016/S0140-6736(98)06425-3
87/47 Bailey et al., 1990 [98] 11.61 360 382 443 Respiratory and adverse effects https://doi.org/10.1097/00000542-199011000-00005
88/33 Greenblatt et al., 1984 [99] 11.27 417 448 653 Pharmacology https://doi.org/10.1097/00000542-198461010-00006
89/78 Quine et al., 1995 [100] 11.27 293 303 464 Sedation aspects https://doi.org/10.1136/gut.36.3.462
90/91 Schmiedlin-Ren et al., 1997 [101] 11.25 270 295 398 Cytochrome P450 approach https://doi.org/10.1124/mol.51.5.741
91/72 Thummel et al., 1994 [102] 11.22 303 314 405 Cytochrome P450 approach https://jpet.aspetjournals.orgcontent/271/1549.long
92/86 Cheng et al., 1996 [103] 11.04 276 300 446 Sedation aspects https://doi.org/10.1016/S0022-5223(96)70062-4
93/65 Hunt et al., 1992 [104] 11.03 320 355 528 Cytochrome P450 approach https://doi.org/10.1016/0006-2952(92)90010-G
94/76 Ashton, 1994 [105] 11.00 297 358 563 Advantages and disadvantages https://doi.org/10.2165/00003495-199448010-00004
95/70 Heinrichs et al., 1992 [106] 10.48 304 338 498 Behavioral evaluation https://doi.org/10.1016/0006-8993(92)90708-H
96/87 Olkkola et al., 1993 [107] 9.82 275 310 383 Pharmacology https://doi.org/10.1038/clpt.1993.25
97/92 Magorian et al., 1993 [108] 9.61 269 323 602 Anesthesia aspects https://doi.org/10.1097/00000542-199311000-00007
98/99 Mangano et al., 1992 [109] 8.83 256 311 489 Analgesia aspects https://doi.org/10.1097/00000542-199203000-00004
99/56 Allonen et al., 1981 [110] 8.63 345 300 433 Effects on the body https://doi.org/10.1038/clpt.1981.217
100/75 Dundee et al., 1984 [7] 8.08 299 296 337 Pharmacology https://doi.org/10.2165/00003495-198428060-00002

a Web of Science Core Collection.